Eli Lilly and Company (NYSE:LLY) Stock Price Up 1.4% – Time to Buy?

Eli Lilly and Company (NYSE:LLY)’s share price shot up 1.4% on Thursday . The company traded as high as $1,189.07 and last traded at $1,172.50. 2,781,459 shares changed hands during mid-day trading, a decline of 13% from the average daily volume of 3,185,476 shares. The stock had previously closed at $1,156.63.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s AtaiBeckley acquisition adds a promising late-stage mental health pipeline, potentially broadening its growth opportunities beyond obesity and diabetes. Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
• Positive Sentiment: Investors are also encouraged by ongoing pipeline momentum, including new clinical-trial updates across obesity, addiction, and other programs that reinforce Lilly’s R&D depth. Eli Lilly Expands Obesity Pipeline With New Phase 1 Eloralintide Trial
• Neutral Sentiment: Analysts are highlighting continued momentum in Lilly’s GLP-1 and amylin efforts, which supports sentiment but does not change near-term fundamentals on its own. Eli Lilly Likely to See More Momentum in GLP-1 Pipeline, UBS Says
• Negative Sentiment: Some commentary says the AtaiBeckley deal is a long-dated bet, since pivotal data for the lead psychedelic program may not arrive until 2029, creating execution and regulatory risk. Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug
• Negative Sentiment: There is also concern that Lilly may be paying up for a speculative asset, which could weigh on returns if the acquired programs fail to deliver. Eli Lilly to Buy AtaiBeckley for Initial $2.8 Billion

Analyst Upgrades and Downgrades

A number of research firms have recently commented on LLY. Barclays raised their price target on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a report on Monday, May 4th. Wall Street Zen upgraded Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 2nd. Bank of America increased their price objective on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Weiss Ratings upgraded Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, July 1st. Finally, Morgan Stanley lifted their target price on Eli Lilly and Company from $1,344.00 to $1,347.00 and gave the company an “overweight” rating in a report on Wednesday, July 8th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $1,283.64.

Eli Lilly and Company Stock Performance

The company’s fifty day simple moving average is $1,110.32 and its 200 day simple moving average is $1,035.14. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The stock has a market capitalization of $1.10 trillion, a P/E ratio of 41.65, a P/E/G ratio of 1.41 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. During the same period in the previous year, the business earned $3.34 EPS. The business’s revenue for the quarter was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 35.5 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Institutional Trading of Eli Lilly and Company

A number of large investors have recently modified their holdings of the business. Willner & Heller LLC raised its stake in shares of Eli Lilly and Company by 1.0% in the second quarter. Willner & Heller LLC now owns 917 shares of the company’s stock worth $1,100,000 after purchasing an additional 9 shares during the last quarter. M.E. Allison & CO. Inc. lifted its holdings in shares of Eli Lilly and Company by 0.7% during the fourth quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company’s stock valued at $1,587,000 after purchasing an additional 10 shares in the last quarter. Tanager Wealth Management LLP boosted its position in shares of Eli Lilly and Company by 2.6% during the fourth quarter. Tanager Wealth Management LLP now owns 395 shares of the company’s stock valued at $424,000 after buying an additional 10 shares during the last quarter. Wealthspan Partners LLC boosted its position in shares of Eli Lilly and Company by 0.5% during the fourth quarter. Wealthspan Partners LLC now owns 2,110 shares of the company’s stock valued at $2,268,000 after buying an additional 10 shares during the last quarter. Finally, Morey & Quinn Wealth Partners LLC increased its holdings in Eli Lilly and Company by 1.5% in the 4th quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company’s stock worth $710,000 after buying an additional 10 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.